FindTrial
Sign In

Which is better for treatment of children with nephrotic syndrome : prednisole dosed based on body weight or body surface area?

Body weight-based prednisolone versus body surface area-based prednisolone regimen for induction of remission in children with nephrotic syndrome

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2014/04/004541
Enrollment
80
Registered
2014-04-11
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Children of 1- 18 years with idiopathic Nephrotic syndrome (NS) including Frequently relapsing NS, Infrequently relapsing NS, Steroid Dependent NS and first episode of NS

Interventions

Intervention1: Prednisolone: Prednisolone shall be administered as body weight-based(2mg/kg/day)regimen orally in two/three divided doses till remission for relapses or till 6 weeks for first episode.

Sponsors

JIPMER
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Children of 1- 18 years with idiopathic Nephrotic Syndrome(NS) including Frequently Relapsing NEphrotic Syndrome (FRNS),Infrequently Relapsing Nephrotic Syndrome (IFRNS),Steroid Dependent Nephrotic Syndrome (SDNS) and first episode of NS.

Exclusion criteria

Exclusion criteria: a) Children with steroid resistant NS (SRNS). b) Children with secondary NS (e.g. lupus nephritis, Ig A nephropathy, Henoch-Schonlein Purpura nephritis). c) Children with active infections. d) Children once enrolled in the study shall not be enrolled again in the study during future relapse. In case any further relapse occurs, they shall be managed with the previous treatment regimen only (in order to ascertain the cumulative dosage of steroid).

Design outcomes

Primary

MeasureTime frame
time taken for remission between body weight-based prednisolone versus Body surface area-based prednisolone regimen in children with NS. Timepoint: number of days taken from start of prednisolone to remission (three consequtive days urine albumin nil). mean difference of 2 days between the two groups is considered significant—

Secondary

MeasureTime frame
Number of relapses,adverse effects of steroids(in the form of hypertension,obesity,cushingoid features,serious infections like peritonitis,cellulitis&pneumonia, eye changes like glaucoma ,cataract&hypertensive retinopathy, deranged HbA1c),cumulative dosage of prednisolone (mg/kg per 6 months),clinical effect in different subtypes of NS between body weight-based prednisolone versus body surface area-based prednisolone regimen in children with NS on a follow up period of 6 months.Timepoint: follow up of 6 months—

Countries

India

Contacts

Public ContactDR VAISHNAVI R

JIPMER

drsriramkris@gmail.com9442121326

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026